GALT News and Press, Galectin Therapeutics Inc. From 11/03/23

Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of belapectin on cardiac repolarization (QT interval) Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new marker of disease progression in patient with portal hypertensi...

NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on Oct...

NORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve on the company’s board of directors. Dr. Carso...

NORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive...

NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20 th edition of the Discovery on Target meeting, the industry’s preeminent eve...

2023-09-14 08:15:00 ET Summary Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibition may be causing poor tolerability and negative c...

NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on Septemb...

NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate in the 9 th Edition of the Paris NASH meeting, where a select group of international e...

2023-08-14 13:19:20 ET Despite recent setbacks, drugmakers are still forging ahead in their quest to develop effective treatments for non-alcoholic steatohepatitis, or NASH, a growing public health concern that could represent a roughly $108B global market opportunity by 2030. According...

2023-08-14 09:29:20 ET Galectin Therapeutics press release ( NASDAQ: GALT ): Q2 GAAP EPS of -$0.15. Cash and cash equivalents of $17.97m For further details see: Galectin Therapeutics GAAP EPS of -$0.15